Targeting Drp1 inhibits ESCC progression via the ROS-PGC1-α-Nrf1/2 pathway
PMCID: PMC12175380
PMID: 40528181
DOI: 10.1186/s12967-025-06697-8
Journal: Journal of translational medicine
Publication Date: 2025-6-17
Authors: Jiang Z, Yang Y, Zhou J, Li X, Meng Q, et al.
Key Points
- Drp1 overexpression is a significant driver of ESCC growth and metastasis
- High Drp1 expression correlates with poor patient prognosis
- miR-203a-3p represents a potential novel therapeutic intervention for ESCC progression
Summary
This study investigated the role of Dynamin-related protein 1 (Drp1) in esophageal squamous cell carcinoma (ESCC) progression, addressing a critical gap in understanding early-stage cancer metastasis mechanisms. By employing comprehensive research methods including database analysis, immunohistochemistry, functional cell experiments, and mouse models, researchers discovered that high Drp1 expression correlates with poor patient prognosis and significantly enhances ESCC cell growth and metastatic potential.
The research revealed a complex molecular mechanism wherein Drp1 overexpression activates the PGC1-α-Nrf1/2 signaling pathway and promotes epithelial-mesenchymal transition (EMT), facilitating tumor cell metastasis. Notably, miR-203a-3p was identified as a potential therapeutic target, demonstrating the ability to down-regulate Drp1 expression and inhibit ESCC cell malignant progression through the ROS-PGC1-α-Nrf1/2 pathway.